PDP1 and neoplasm: Mice administered RGD4C.PDP-sTRAIL showed clear decrease of tumor size from day 0 to day 14 after treatment (Figure 7A), followed by a significant decrease in tumor luminescence over time, reflecting tumor viability, in mice treated with the RGD4C.PDP-sTRAIL (Figure 7B).